"Our relationship with BD has been very successful over the past two years, and this is the next logical step to elevate our infusion technologies," said Swi Barak, founder of CME. "This transaction will create new opportunities for our people and our technology that we wouldn't have been able to achieve alone."
The acquisition of CME expands BD's infusion portfolio to include ambulatory, home, and specialty acute care infusion pumps. CME designs, manufactures and markets a range of infusion and syringe pumps as well as related accessories and disposable administration sets for both homecare and hospital settings. CME infusion pumps are known for their compact and highly portable design, making them ideal for specialty applications such as IV and epidural anesthesia and pain management, hospital and home nutrition, among others.
"The integration of CME's technology into BD will strengthen our strategy of reinventing medication management across the health care continuum," said Mike Garrison, vice president and general manager of worldwide Infusion Solutions for BD. "The acquisition of CME advances our mission to provide efficient end-to-end IV safety solutions across a broad journey of care."
This transaction completes the acquisition of the remaining 60 percent of CME. CareFusion had initially acquired a non-controlling 40 percent stake of CME in 2014. Additional terms of the transaction were not disclosed.